Peritoneovenous shunt for treatment of refractory chylous ascites
10.3760/cma.j.cn113855-20220124-00047
- VernacularTitle:腹腔-静脉分流术治疗难治性乳糜腹水的疗效分析
- Author:
Kun CHANG
1
;
Song XIA
;
Yuguang SUN
;
Jianfeng XIN
;
Wenbin SHEN
Author Information
1. 首都医科大学附属北京世纪坛医院淋巴外科，北京 100038
- Keywords:
Chylous ascites;
Peritoneovenous shunt
- From:
Chinese Journal of General Surgery
2022;37(9):660-664
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate peritoneovenous shunt for treatment of refractory chylous ascites.Methods:The clinical data of 40 patients with refractory chylous ascites treated by peritoneovenous shunt procedure at Department of Lymphatic Surgery, Beijing Shijitan Hospital, Capital Medical University from May 2008 to Aug 2020 were retrospectively analyzed.Results:Patients'postoperative weight [(57.8±13.2) kg] was significantly lower than that of preoperative weight [(65.9±13.1) kg]. Postoperative abdominal circumference significantly reduced [(82.0±9.8) cm vs. (94.3±10.8) cm]. Average postoperative 24-hour urine output was significantly higher than that before operation [2 250 (1 650, 3 300) ml vs. 750 (500, 1 000) ml]. Platelet count and fibrinogen decreased after operation; prothrombin time (PT) prolonged; the change of time of activated partial thromboplastin (APTT) was not statistically significant ( P=0.506). Postoperative aspartate aminotransferase (AST), urea, and creatinine decreased; whereas alanine aminotransferase (ALT) ( P=0.154), total protein ( P=0.350), and albumin ( P=0.113) remained unchanged. 35 patients got follow-up, 29 deceased. The survival time with tube was 16 (7,37) months; 6 cases survived, the survival time with tube was 28 (6,124) months. Conclusions:Peritoneovenous shunt is a palliative surgery improving the quality of life of patients with refractory chylous ascites.
